Literature DB >> 23922301

Adoptive T-cell therapy for cancer: boutique therapy or treatment modality?

Cassian Yee1.   

Abstract

Adoptive cellular therapy, involving the ex vivo enrichment and expansion of antigen-specific immune cells for adoptive transfer, has emerged as an increasingly effective modality for the treatment of patients with advanced cancer refractory to conventional therapy. ©2013 AACR.

Entities:  

Mesh：

Year:  2013        PMID： 23922301      PMCID： PMC3830944          DOI： 10.1158/1078-0432.CCR-13-1367

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Udai S Kammula; Marybeth S Hughes; Giao Q Phan; Deborah E Citrin; Nicholas P Restifo; Paul F Robbins; John R Wunderlich; Kathleen E Morton; Carolyn M Laurencot; Seth M Steinberg; Donald E White; Mark E Dudley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

2.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

Authors:  Naomi N Hunder; Herschel Wallen; Jianhong Cao; Deborah W Hendricks; John Z Reilly; Rebecca Rodmyre; Achim Jungbluth; Sacha Gnjatic; John A Thompson; Cassian Yee
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

3.  IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response.

Authors:  Yongqing Li; Marie Bleakley; Cassian Yee
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

Review 4.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

5.  Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.

Authors:  Aude G Chapuis; John A Thompson; Kim A Margolin; Rebecca Rodmyre; Ivy P Lai; Kaye Dowdy; Erik A Farrar; Shailender Bhatia; Daniel E Sabath; Jianhong Cao; Yongqing Li; Cassian Yee
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-05       Impact factor: 11.205

6.  Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells.

Authors:  Marcus O Butler; Philip Friedlander; Matthew I Milstein; Mary M Mooney; Genita Metzler; Andrew P Murray; Makito Tanaka; Alla Berezovskaya; Osamu Imataki; Linda Drury; Lisa Brennan; Marisa Flavin; Donna Neuberg; Kristen Stevenson; Donald Lawrence; F Stephen Hodi; Elsa F Velazquez; Michael T Jaklitsch; Sara E Russell; Martin Mihm; Lee M Nadler; Naoto Hirano
Journal:  Sci Transl Med       Date:  2011-04-27       Impact factor: 17.956

7.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

8.  In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.

Authors:  D J Schwartzentruber; S S Hom; R Dadmarz; D E White; J R Yannelli; S M Steinberg; S A Rosenberg; S L Topalian
Journal:  J Clin Oncol       Date:  1994-07       Impact factor: 44.544

9.  Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.

Authors:  Michal J Besser; Ronnie Shapira-Frommer; Orit Itzhaki; Avraham J Treves; Douglas B Zippel; Daphna Levy; Adva Kubi; Noa Shoshani; Dragoslav Zikich; Yaara Ohayon; Daniel Ohayon; Bruria Shalmon; Gal Markel; Ronit Yerushalmi; Sara Apter; Alon Ben-Nun; Eytan Ben-Ami; Avichai Shimoni; Arnon Nagler; Jacob Schachter
Journal:  Clin Cancer Res       Date:  2013-05-20       Impact factor: 12.531

10.  Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.

Authors:  Khoi Q Tran; Juhua Zhou; Katherine H Durflinger; Michelle M Langhan; Thomas E Shelton; John R Wunderlich; Paul F Robbins; Steven A Rosenberg; Mark E Dudley
Journal:  J Immunother       Date:  2008-10       Impact factor: 4.456
View more
  14 in total

1.  The Efficacy of CIK-Based Immunotherapies for Advanced Solid Tumors.

Authors:  Hongjin Chu; Fengcai Du; Lixin Jiang; Zhixin Wang; Zhaohua Gong; Peiwen Lian; Peng Li; Jian Chen
Journal:  Technol Cancer Res Treat       Date:  2016-07-19

2.  Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells.

Authors:  Bonnie Huang; Wuhbet D Abraham; Yiran Zheng; Sandra C Bustamante López; Samantha S Luo; Darrell J Irvine
Journal:  Sci Transl Med       Date:  2015-06-10       Impact factor: 17.956

3.  Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.

Authors:  Jiang Li; Qiu-Yan Chen; Jia He; Ze-Lei Li; Xiao-Feng Tang; Shi-Ping Chen; Chuan-Miao Xie; Yong-Qiang Li; Li-Xi Huang; Shu-Bio Ye; Miao-La Ke; Lin-Quan Tang; Huai Liu; Lu Zhang; Shan-Shan Guo; Jian-Chuan Xia; Xiao-Shi Zhang; Li-Min Zheng; Xiang Guo; Chao-Nan Qian; Hai-Qiang Mai; Yi-Xin Zeng
Journal:  Oncoimmunology       Date:  2015-03-06       Impact factor: 8.110

Review 4.  Pathogen-driven cancers and emerging immune therapeutic strategies.

Authors:  Natalie Vandeven; Paul Nghiem
Journal:  Cancer Immunol Res       Date:  2014-01       Impact factor: 11.151

Review 5.  Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy.

Authors:  Shirin Karimi; Subhasis Chattopadhyay; Nitya G Chakraborty
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

6.  A Synthetic CD8α:MyD88 Coreceptor Enhances CD8+ T-cell Responses to Weakly Immunogenic and Lowly Expressed Tumor Antigens.

Authors:  Sabina Kaczanowska; Ann Mary Joseph; Jitao Guo; Alexander K Tsai; Jackline Joy Lasola; Kenisha Younger; Yuji Zhang; Cruz Velasco Gonzales; Eduardo Davila
Journal:  Cancer Res       Date:  2017-10-20       Impact factor: 12.701

Review 7.  Cancer immunotherapy: the beginning of the end of cancer?

Authors:  Sofia Farkona; Eleftherios P Diamandis; Ivan M Blasutig
Journal:  BMC Med       Date:  2016-05-05       Impact factor: 8.775

Review 8.  Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells.

Authors:  Pappanaicken R Kumaresan; Thiago Aparecido da Silva; Dimitrios P Kontoyiannis
Journal:  Front Immunol       Date:  2018-01-08       Impact factor: 7.561

9.  Cellular immunity augmentation in mainstream oncologic therapy.

Authors:  Daohong Chen; Xiaoshi Zhang
Journal:  Cancer Biol Med       Date:  2017-05       Impact factor: 4.248

Review 10.  Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

Authors:  Fernando Aranda; Erika Vacchelli; Florine Obrist; Alexander Eggermont; Jérôme Galon; Wolf Hervé Fridman; Isabelle Cremer; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-05-01       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.